公开(公告)号：US10800760B2

公开(公告)日：2020-10-13

申请号：US15993214

申请日：2018-05-30

申请人： NantBio, Inc.

发明人： Chunlin Tao ,  Qinwei Wang ,  Sharif Asad ,  Paul Weingarten ,  Sherry Ci

IPC分类号： C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14

摘要： The present invention relates to the use of substituted pyrazole derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrazole derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

公开(公告)号：US20180346451A1

公开(公告)日：2018-12-06

申请号：US15992989

申请日：2018-05-30

申请人： NantBio, Inc.

发明人： Chunlin Tao ,  Qinwei Wang ,  Sharif Asad ,  Paul Weingarten ,  Sherry Ci

IPC分类号： C07D403/14 ,  A61P25/28 ,  A61P29/00 ,  A61P35/00

摘要： The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

公开(公告)号：US20180201610A1

公开(公告)日：2018-07-19

申请号：US15874485

申请日：2018-01-18

申请人： Nantbio, Inc.

发明人： Chunlin Tao ,  Laxman Nallan ,  David G. Ho ,  Qinwei Wang ,  Paul Weingarten ,  Anna B. Juncker-Jensen

IPC分类号： C07D417/14 ,  A61P35/00

CPC分类号： C07D417/14 ,  A61P35/00

摘要： Compounds and compositions are presented that inhibit K-Ras, and especially mutant K-Ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.

公开(公告)号：US20240352533A1

公开(公告)日：2024-10-24

申请号：US18643905

申请日：2024-04-23

申请人： NantBio, Inc.

发明人： Paul Weingarten

IPC分类号： C12Q1/6886 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  G01N33/57484 ,  C12Q2600/106 ,  C12Q2600/158

摘要： Compositions and methods for treatment of tumor cells are presented in which tumor cells that overexpress monocarboxylate transporter 4 (Mct-4), HIF-1α, Hexokinase-2, and/or CD147 are targeted with one or more metabolic inhibitors.

公开(公告)号：US10736884B2

公开(公告)日：2020-08-11

申请号：US16441980

申请日：2019-06-14

申请人： NANTBIO, INC. ,  NANTOMICS, LLC ,  NANT HOLDINGS IP, LLC

发明人： Shahrooz Rabizadeh ,  Oleksandr Buzko ,  Paul Weingarten ,  Heather McFarlane ,  Connie Tsai ,  Stephen Charles Benz ,  Kayvan Niazi ,  Patrick Soon-Shiong

IPC分类号： A61K31/4196 ,  A61K31/538 ,  A61K45/06 ,  A61P35/00 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4439

摘要： Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.

公开(公告)号：US20180346450A1

公开(公告)日：2018-12-06

申请号：US15993214

申请日：2018-05-30

申请人： NantBio, Inc.

发明人： Chunlin Tao ,  Qinwei Wang ,  Sharif Asad ,  Paul Weingarten ,  Sherry Ci

IPC分类号： C07D403/12 ,  C07D401/14 ,  C07D405/14

摘要： The present invention relates to the use of substituted pyrazole derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrazole derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

公开(公告)号：US10738033B2

公开(公告)日：2020-08-11

申请号：US15992989

申请日：2018-05-30

申请人： NantBio, Inc.

发明人： Chunlin Tao ,  Qinwei Wang ,  Sharif Asad ,  Paul Weingarten ,  Sherry Ci

IPC分类号： C07D403/14 ,  A61P35/00 ,  A61P29/00 ,  A61P25/28 ,  A61K31/4155

摘要： The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. The present invention also provides compounds of the formula: as defined herein.

公开(公告)号：US10525040B2

公开(公告)日：2020-01-07

申请号：US15738353

申请日：2016-06-29

申请人： NANTBIO, INC. ,  NANTOMICS, LLC ,  NANT HOLDINGS IP, LLC

发明人： Shahrooz Rabizadeh ,  Oleksandr Buzko ,  Paul Weingarten ,  Heather McFarlane ,  Connie Tsai ,  Stephen Charles Benz ,  Kayvan Niazi ,  Patrick Soon-Shiong

IPC分类号： A61K31/4196 ,  A61K45/06 ,  A61K31/538 ,  A61P35/00 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4439

摘要： Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.

公开(公告)号：US10344026B2

公开(公告)日：2019-07-09

申请号：US15874485

申请日：2018-01-18

申请人： NANTBIO, INC.

发明人： Chunlin Tao ,  Laxman Nallan ,  David G. Ho ,  Qinwei Wang ,  Paul Weingarten ,  Anna B. Juncker-Jensen

IPC分类号： A61P35/00 ,  C07D417/14

摘要： Compounds and compositions are presented that inhibit K-Ras, and especially mutant K-Ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.